Pharmacotherapy

Papers
(The H4-Index of Pharmacotherapy is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Warfarin dosage in a postpartum woman while breastfeeding: A case report78
Assessment and management of iatrogenic withdrawal syndrome and delirium in pediatric intensive care units across Europe: An ESPNIC survey73
Characterization of lamotrigine disposition changes during and after pregnancy in women with epilepsy57
43
Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps39
Empiric dosing strategies to predict lamotrigine concentrations during pregnancy39
Association of bleeding with serotonergic antidepressants in patients receiving left ventricular assist device support38
Safety and efficacy of cefiderocol for off‐label treatment indications: A systematic review38
Changes in serum potassium in people with type 2 diabetes taking sodium‐glucose co‐transporter‐2 inhibitors32
Treatment of patients with serious infections due to carbapenem‐resistant Acinetobacter baumannii: How viable are the current options?31
Update and narrative review of avian influenza (H5N1) infection in adult patients30
Comparison of risk‐scoring systems for heparin‐induced thrombocytopenia in cardiac surgery patients30
Issue Information29
Acid‐suppressive drugs: A systematic review and network meta‐analysis of their nocturnal acid‐inhibitory effect29
Impact of concurrent gabapentin or pregabalin with high‐dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant26
Reduced risk of NSAID‐Induced adverse events with concomitant use of misoprostol (MICRO study)26
Response to comment on “Dosing implications for liposomal amphotericin B in pregnancy”25
Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment‐experienced and/or have multidrug‐resistant HIV‐1: Endorse24
Comment on “Evaluation of the safety and tolerability of intravenous undiluted levetiracetam at a pediatric institution”24
Role of maternal COVID‐19 vaccination in providing immunological protection to the newborn23
Evaluation of the safety and tolerability of intravenous undiluted levetiracetam at a pediatric institution23
Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures21
0.084309101104736